Lentiviral and other retroviral vectors in 2018: Applications, production and vector design relevant for translation into human.
Lentviral and retroviral vectors are at the forefront of advanced therapeutic medicinal product (ATMP) development. The 1-day BSGCT Annual Conference in April 2018 aims to give the attendee an overview about the successes, challenges and areas for future development. The programme is exciting and key national and international speakers including Adrian Thrasher and Luigi Naldini have accepted the invitation to speak. The conference will close with a moderated questions and answers session, debating the pros and cons of gene editing versus gene addition-based strategies.
An important aspect of our conference is to give early career gene and cell therapists a chance to become involved. This year we will, for the first time, include a session on 1-minute oral poster speed talks. Younger members of the BSGCT community will also be invited to co-chair sessions and validate submitted abstract; important skills to learn, but also valuable additions to CVs.
Arrange to meet with your local Cobra representatives Alex Brownfield, Philip Ridley-Smith (pictured) and George Prout at Regents Conference & Events Centre, London, who will be exhibiting at stand number 8.